drugset / Trial / NCT02674269

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

NCT02674269

Phase 1/2 Withdrawn UroGen Pharma Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.

Timeline

Start
2016-10
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 300 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 400 iu Other

Indications